Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

8.3K
A primary culture of bovine corneal endothelial cells was used to investigate the mechanism of corneal endothelial-mesenchymal transition. Furthermore, a rat corneal endothelium cryoinjury model was used to demonstrate corneal endothelial-mesenchymal transition in...
8.3K
A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition08:38

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

1.7K
This work presents an animal model of endothelial-to-mesenchymal transition-induced fibrosis, as seen in congenital cardiac defects such as critical aortic stenosis or hypoplastic left heart syndrome, which allows for detailed histological tissue evaluation, the identification of regulatory signaling pathways, and the testing of treatment options.
1.7K
TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing07:05

TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

5.7K
We describe methods to investigate TGF-β2-induced EndMT in endothelial cells by observing cell morphology changes and examining the expression EndMT-related marker changes using immunofluorescence staining. CRISPR/Cas9 gene editing was described and used to deplete the gene encoding Snail to investigate its role in TGF-β2-induced...
5.7K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

36.5K
A straightforward method is described for the induction of epithelial to mesenchymal transition (EMT) in a variety of cell types. Methods for the analysis of cells in EMT states by immunocytochemistry are...
36.5K
Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

11.7K
A protocol for in vitro induction of endothelial-mesenchymal transition (EndMT), which is useful for investigating cellular signaling pathways involved in EndMT, is described. In this experimental model, EndMT is induced by treatment with TGF-β in MS-1 endothelial...
11.7K
Detection of Alternative Splicing During Epithelial-Mesenchymal Transition11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

13.3K
Alternative splicing regulation has been shown to contribute to the epithelial-mesenchymal transition (EMT), an essential cellular program in various physiological and pathological processes. Here we describe a method utilizing an inducible EMT model for the detection of alternative splicing during...
13.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T Cells.

Pharmaceutics·2026
Same author

Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.

The lancet. Gastroenterology & hepatology·2026
Same author

Absorption, distribution, metabolism and excretion of SUL-138 in rats and minipigs.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.

The lancet. Gastroenterology & hepatology·2025
Same author

SUL-138 mitigates accelerated endothelial aging and protects the kidney.

Clinical science (London, England : 1979)·2025

Related Experiment Video

Updated: Jan 19, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.3K

Non-coding RNA in endothelial-to-mesenchymal transition.

Melanie S Hulshoff1,2,3, Gonzalo Del Monte-Nieto4, Jason Kovacic5

  • 1Laboratory for Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), Groningen, The Netherlands.

Cardiovascular Research
|September 11, 2019
PubMed
Summary

Non-coding RNAs regulate endothelial-to-mesenchymal transition (EndMT), a process implicated in development and diseases like fibrosis and cancer. This review explores how these RNAs influence EndMT and their therapeutic potential for cardiovascular disease.

Keywords:
Cardiac developmentCardiovascular diseaseEndothelial-mesenchymal transition (EndMT)Non-coding RNAPlasticity

More Related Videos

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.7K
TGF-β-mediated Endothelial to Mesenchymal Transition EndMT and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing
07:05

TGF-β-mediated Endothelial to Mesenchymal Transition EndMT and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

Published on: February 26, 2021

5.7K

Related Experiment Videos

Last Updated: Jan 19, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
09:05

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition

Published on: August 20, 2016

8.3K
Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

1.7K
TGF-β-mediated Endothelial to Mesenchymal Transition EndMT and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing
07:05

TGF-β-mediated Endothelial to Mesenchymal Transition EndMT and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing

Published on: February 26, 2021

5.7K

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Developmental Biology

Background:

  • Endothelial-to-mesenchymal transition (EndMT) is crucial for embryonic development but contributes to adult pathologies like organ fibrosis, cardiovascular disease, and cancer.
  • Non-coding RNAs, encompassing microRNAs, long non-coding RNAs, and circular RNAs, are key regulators of EndMT.
  • Dysregulated EndMT in adulthood is a significant factor in fibroproliferative cardiovascular diseases.

Purpose of the Study:

  • To review the mechanisms by which non-coding RNAs modulate EndMT during development and disease.
  • To explore the therapeutic potential of non-coding RNAs for treating fibroproliferative cardiovascular diseases.

Main Methods:

  • Literature review of studies on non-coding RNAs and EndMT.
  • Analysis of mechanisms by which non-coding RNAs facilitate or inhibit EndMT.
  • Evaluation of therapeutic strategies targeting non-coding RNAs for cardiovascular conditions.

Main Results:

  • Non-coding RNAs play diverse roles in controlling EndMT.
  • Specific non-coding RNAs can either promote or suppress EndMT.
  • Understanding these regulatory roles is essential for therapeutic interventions.

Conclusions:

  • Non-coding RNAs are critical regulators of EndMT in both development and disease.
  • Targeting non-coding RNAs offers a promising therapeutic avenue for fibroproliferative cardiovascular diseases.
  • Further research into non-coding RNA mechanisms can lead to novel treatments for cardiovascular pathologies.